STAT3 and non-small cell lung carcinoma: Gefitinib (Iressa) is an inhibitor of EGFR-tyrosine kinase that inhibits EGFR-dependent but not IL-6-dependent phosphorylation of STAT3, and is clinically used to treat non-small cell lung cancer patients with EGFR-activating mutations [23].